Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026)
Elanco Animal Health's (ELAN) quarterly Total Non-Current Liabilities came in at $6.4 billion in Q2 2026, up 1.47% year-over-year from $6.3 billion in Q2 2025, and up 2.67% quarter-over-quarter from $6.3 billion in Q1 2026.
Analysis
Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $6.4 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 1.47% year-over-year to $6.4 billion; the TTM figure through Jun 2026 stood at $6.4 billion (up 1.47% YoY), while the FY2025 annual figure was $6.2 billion, changed 0.16% from the prior year.
- Total Non-Current Liabilities came in at $6.4 billion for Q2 2026 at Elanco Animal Health, up from $6.3 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $8.4 billion in Q1 2022 to a low of $6.1 billion in Q1 2025.
- Average Total Non-Current Liabilities over 5 years is $7.2 billion, with a median of $7.4 billion recorded in 2024.
- Year-over-year, Total Non-Current Liabilities decreased 20.64% in 2024 and grew 2.52% in 2026.
- Over 5 years, Total Non-Current Liabilities stood at $8.0 billion in 2022, then slipped by 3.07% to $7.7 billion in 2023, then fell by 19.57% to $6.2 billion in 2024, then advanced by 0.16% to $6.2 billion in 2025, then advanced by 3.15% to $6.4 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $6.4 billion in Q2 2026, $6.3 billion in Q1 2026, and $6.2 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 542.10 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 11.64 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 6.42 Bn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 1.02 Bn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 10.82 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | 1.31 Mn |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.42 Bn |
| Mar 31, 2026 | 6.26 Bn |
| Dec 31, 2025 | 6.23 Bn |
| Sep 30, 2025 | 6.20 Bn |
| Jun 30, 2025 | 6.33 Bn |
| Mar 31, 2025 | 6.10 Bn |
| Dec 31, 2024 | 6.22 Bn |
| Sep 30, 2024 | 6.17 Bn |
| Jun 30, 2024 | 7.36 Bn |
| Mar 31, 2024 | 7.49 Bn |
| Dec 31, 2023 | 7.73 Bn |
| Sep 30, 2023 | 7.78 Bn |
| Jun 30, 2023 | 7.97 Bn |
| Mar 31, 2023 | 8.04 Bn |
| Dec 31, 2022 | 7.97 Bn |
| Sep 30, 2022 | 7.98 Bn |
| Jun 30, 2022 | 8.22 Bn |
| Mar 31, 2022 | 8.40 Bn |
| Dec 31, 2021 | 8.71 Bn |
| Sep 30, 2021 | 8.66 Bn |